menu
    • menu

    Find Olaparib manufacturers, exporters & distributors on PharmaCompass

    Axplora Olaparib

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Olaparib

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Synopsis

    Related ProductsRelated Products

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: 763113-22-0, Lynparza, Azd2281, Azd-2281, Ku-0059436, Azd 2281
    Molecular Formula
    C24H23FN4O3
    Molecular Weight
    434.5  g/mol
    InChI Key
    FDLYAMZZIXQODN-UHFFFAOYSA-N
    FDA UNII
    WOH1JD9AR8
    Olaparib
    Olaparib is a small molecule inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential chemosensitizing, radiosensitizing, and antineoplastic activities. Olaparib selectively binds to and inhibits PARP, inhibiting PARP-mediated repair of single strand DNA breaks; PARP inhibition may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins and can be activated by single-stranded DNA breaks.
    Olaparib is a Poly(ADP-Ribose) Polymerase Inhibitor. The mechanism of action of olaparib is as a Poly(ADP-Ribose) Polymerase Inhibitor.
    1 2D Structure

    Olaparib

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    4-[[3-[4-(cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorophenyl]methyl]-2H-phthalazin-1-one
    2.1.2 InChI
    InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)
    2.1.3 InChI Key
    FDLYAMZZIXQODN-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F
    2.2 Other Identifiers
    2.2.1 UNII
    WOH1JD9AR8
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Azd 2281

    2. Azd-2281

    3. Azd221

    4. Azd2281

    5. Lynparza

    2.3.2 Depositor-Supplied Synonyms

    1. 763113-22-0

    2. Lynparza

    3. Azd2281

    4. Azd-2281

    5. Ku-0059436

    6. Azd 2281

    7. 1-(cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]piperazine

    8. Olaparib (azd-2281)

    9. 4-(3-(4-(cyclopropanecarbonyl)piperazine-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2h)-one

    10. Ku-59436

    11. Olaparib (azd2281, Ku-0059436)

    12. 4-[[3-[4-(cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorophenyl]methyl]-2h-phthalazin-1-one

    13. Az2281

    14. Mfcd13185161

    15. Woh1jd9ar8

    16. Nsc-747856

    17. C24h23fn4o3

    18. Chebi:83766

    19. 4-(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorobenzyl)phthalazin-1(2h)-one

    20. 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-one

    21. Az-2281

    22. Keylynk-010 Component Olaparib

    23. Ku59436

    24. Olaparib Component Of Keylynk-010

    25. Olaparib [inn]

    26. Olaparib Cpd

    27. Olaparib (azd2281; Ku-0059436)

    28. Olaparib [usan:inn]

    29. Unii-woh1jd9ar8

    30. Olaparib (azd2281)

    31. Acylpiperazine Analogue, 47

    32. Olaparibum

    33. Azd221

    34. 4-[3-[4-(cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorobenzyl]phthalazin-1(2h)-one

    35. Olaparib- Bio-x

    36. Lynparza (tn)

    37. 09l

    38. 4-((3-((4-(cyclopropylcarbonyl)piperazin-1-yl)carbonyl)-4-fluorophenyl)methyl)phthalazin-1(2h)-one

    39. 4-((3-{(4-(cyclopropylcarbonyl)piperazin-1-yl)carbonyl}-4-fluorophenyl)methyl)phthalazin-1(2h)-one

    40. 4-[(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorophenyl)methyl]phthalazin-1(2h)-one

    41. Ku 59436

    42. Olaparib [usan]

    43. Olaparib [jan]

    44. Ku0059436

    45. Olaparib [mi]

    46. Olaparib [vandf]

    47. Olaparib - Azd2281

    48. Olaparib [mart.]

    49. Olaparib [who-dd]

    50. Azd-2281 (olaparib)

    51. Olaparib (jan/usan/inn)

    52. Mls006010185

    53. Schembl426568

    54. Olaparib [orange Book]

    55. Chembl521686

    56. Gtpl7519

    57. Bdbm27566

    58. Dtxsid60917988

    59. Ex-a002

    60. Bcpp000360

    61. Hms3295i09

    62. Hms3426c03

    63. Hms3654g13

    64. Hms3746k07

    65. Hms3870h03

    66. Amy10295

    67. Bcp01872

    68. 763113-22-0, Lynparza,

    69. Nsc747856

    70. Nsc753686

    71. S1060

    72. Zinc40430143

    73. Akos005145764

    74. Ac-7939

    75. Bcp9000363

    76. Ccg-264799

    77. Cs-0075

    78. Db09074

    79. Ex-7210

    80. Nsc 747856

    81. Nsc-753686

    82. Sb14617

    83. Ss-4573

    84. Azd2281,olaparib, Ku-0059436

    85. Ncgc00238451-01

    86. Ncgc00238451-02

    87. Ncgc00238451-08

    88. Ncgc00238451-09

    89. Ncgc00238451-11

    90. 4-[(3-{[4-cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2h)-one

    91. 4-[[3-[[4-(cyclopropylcarbonyl)-1-piperazinyl]carbonyl]-4-fluorophenyl]methyl]-1(2h)-phthalazinone

    92. Bo164169

    93. Hy-10162

    94. Smr004701291

    95. Sy040527

    96. Olaparib(azd2281,kudosku-0059436)

    97. A9666

    98. Bb 0260909

    99. Ft-0651458

    100. Ku 0059436

    101. Sw218142-2

    102. Ec-000.2324

    103. D09730

    104. J-503540

    105. Q7083106

    106. Brd-k02113016-001-08-9

    107. Brd-k02113016-001-09-7

    108. 1-(cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazine

    109. 4-(3-(1-(cyclopropanecarbonyl)piperazine-4-carbonyl)-4-fluorobenzyl)phthalazin-1(2h)-one

    110. (2h)-phthalazinone, 4-((3-((4-(cyclopropylcarbonyl)-1-piperazinyl)carbonyl)-4-fluorophenyl)methyl)-

    111. 1(2h)-phthalazinone, 4-((3-((4-(cyclopropylcarbonyl)-1-piperazinyl)carbonyl)-4-fluorophenyl)methyl)-

    112. 1021843-02-6

    113. 4-({3-[(4-cyclopropanecarbonylpiperazin-1-yl)carbonyl]-4-fluorophenyl}methyl)-1,2-dihydrophthalazin-1-one

    114. Piperazine, 1-(cyclopropylcarbonyl)-4-(5-((3,4-dihydro-4-oxo-1-phthalazinyl)methyl)-2-fluorobenzoyl)-

    2.4 Create Date
    2008-02-11
    3 Chemical and Physical Properties
    Molecular Weight 434.5 g/mol
    Molecular Formula C24H23FN4O3
    XLogP31.9
    Hydrogen Bond Donor Count1
    Hydrogen Bond Acceptor Count5
    Rotatable Bond Count4
    Exact Mass434.17541877 g/mol
    Monoisotopic Mass434.17541877 g/mol
    Topological Polar Surface Area82.1 Ų
    Heavy Atom Count32
    Formal Charge0
    Complexity790
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of: - Ovarian cancer, in which the medication is intended for [a] the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy, or [b] for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for olaparib. - Breast cancer, in which the medication is intended for use in patients with deleterious or suspected deleterious gBRCAm, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine treatment. Select patients for therapy based on an FDA-approved companion diagnostic for olaparib.

    FDA Label

    * Ovarian cancer :

    Lynparza is indicated as monotherapy for the:

    - maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.

    - maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.

    Lynparza in combination with bevacizumab is indicated for the:

    - maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability (see section 5. 1).

    * Breast cancer :

    Lynparza is indicated as monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2 negative locally advanced or metastatic breast cancer . Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments (see section 5. 1).

    Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy.

    * Adenocarcinoma of the pancreas:

    Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen.

    * Prostate cancer :

    Lynparza is indicated as monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.

    Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed BRCA mutated (germline and/or somatic) high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) to platinum based chemotherapy.

    5 Pharmacology and Biochemistry
    5.1 Pharmacology

    The effect of olaparib on cardiac repolarization was assessed in 119 patients following a single dose of 300 mg and in 109 patients following multiple dosing of 300 mg twice daily. No clinically relevant effect of olaparib on QT interval was observed.

    5.2 MeSH Pharmacological Classification

    Antineoplastic Agents

    Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)

    Poly(ADP-ribose) Polymerase Inhibitors

    Chemicals and drugs that inhibit the action of POLY(ADP-RIBOSE)POLYMERASES. (See all compounds classified as Poly(ADP-ribose) Polymerase Inhibitors.)

    5.3 FDA Pharmacological Classification
    5.3.1 Active Moiety
    OLAPARIB
    5.3.2 FDA UNII
    WOH1JD9AR8
    5.3.3 Pharmacological Classes
    Poly(ADP-Ribose) Polymerase Inhibitors [MoA]; Poly(ADP-Ribose) Polymerase Inhibitor [EPC]
    5.4 ATC Code

    L01XK01

    L - Antineoplastic and immunomodulating agents

    L01 - Antineoplastic agents

    L01X - Other antineoplastic agents

    L01XK - Poly (adp-ribose) polymerase (parp) inhibitors

    L01XK01 - Olaparib

    5.5 Absorption, Distribution and Excretion

    Absorption

    Following oral administration, the absorption of olaparib is very rapid and can reach a peak concentration ranging between 4.7 and 9.1 mcg/ml after 1-3 hours. The reported AUC of olaparib after a dose of 200 mg is of 25.8 mcg.h/L and this AUC can be increased by 26% with constant administration. The consumption of a high-fat diet with olaparib can only decrease the tmax but do not have an effect in the peak concentration.

    Route of Elimination

    From the administered dose, approximately 86% of the administered dose is recovered after 7 days from which 44% is found in the urine and 42% is obtained in feces.

    Volume of Distribution

    After administration of a dose of 100 mg/kg, the reported volume of distribution was of 40.3 L.

    Clearance

    The total clearance of olaparib was reported to be 4.6 L/h.

    5.6 Metabolism/Metabolites

    Olaparib is extensively metabolized in the liver by the action of CYP3A isoenzymes. From the administered dose, the unchanged form of olaparib accounted for 70% of the circulating dose and it was considered the major component in urine and feces. The metabolic pathway of olaparib is mainly attributable to oxidation reactions with subsequent glucuronide and sulfate conjugation. However, the over 20 metabolites found in plasma, urine, and feces represented a minor portion of the administered dose. The major circulating metabolites were represented by the mono-oxygenated form and the piperazin-3-ol form.

    5.7 Biological Half-Life

    The reported elimination half-life ranges between 5 to 11 hours.

    5.8 Mechanism of Action

    Olaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are involved in normal cellular homeostasis, such as DNA transcription, cell cycle regulation, and DNA repair. Olaparib has been shown to inhibit growth of select tumor cell lines in vitro and decrease tumor growth in mouse xenograft models of human cancer both as monotherapy or following platinum-based chemotherapy. Increased cytotoxicity and anti-tumor activity following treatment with olaparib were noted in cell lines and mouse tumor models with deficiencies in BRCA. In vitro studies have shown that olaparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complex, resulting in disruption of cellular homeostasis and cell death.

    API SUPPLIERS

    read-more
    read-more

    01

    Axplora

    Germany

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothAxplora- The partner of choice for complex APIs.

    Contact Supplier Contact Supplier
    Flag Germany
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Axplora CB

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Dr. Reddy's Laboratories

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2022-04-19

    Pay. Date : 2022-03-31

    DMF Number : 35742

    Submission : 2021-03-30

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC arrow-down
    ✖

    NDC Package Code : 71796-034

    Start Marketing Date : 2021-11-01

    End Marketing Date : 2024-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

     KDMF VMF Others AUDIT
    Dr Reddy Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Biophore India Pharmaceuticals Pvt...

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    iPHEX India
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothBiophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 40467

    Submission : 2024-09-28

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Biophore

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    LGM Pharma

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothLGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Contact Supplier Contact Supplier
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    LGM Pharma CB

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Rochem International Inc

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Suppliers Night Expo
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothRochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Contact Supplier Contact Supplier
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Rochem

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Aarti Pharmalabs

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothAarti Pharmalabs is a partner of choice for APIs & Intermediates and the largest Indian manufacturer of Xanthine Derivatives.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Aarti Industries Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Chongqing Sintaho Pharmaceutical

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothChongqing Sintaho Pharma: A trusted partner globally for chemosynthetic APIs.

    Contact Supplier Contact Supplier
    Flag China
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Chongqing Sintaho Pharmaceutical

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Jinan Tantu Chemicals

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI China
    Exhibiting
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothJinan Tantu Chemicals offers customized R&D services & production of small molecule APIs & pharmaceutical intermediates.

    Contact Supplier Contact Supplier
    Flag China
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Jinan Tantu Chemicals

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Tofigh Daru

    Iran

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothTofigh Daru develops & synthesizes a diverse range of APIs in Anticancer, Narcotics, Cardiovascular to Immunomodulatory Segments.

    Contact Supplier Contact Supplier
    Flag Iran
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Tofigh Daru

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Glenmark Life Sciences

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Pharma, Lab & Chemical Expo
    Not Confirmed
    arrow

    Glenmark Life Sciences

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 38957

    Submission : 2023-09-28

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    API Reference Price

    read-more
    read-more
    [{"dataSource":"API Export","activeIngredients":"OLAPARIB","year":"2021","qtr":"Q1","strtotime":1613673000,"product":"OLAPARIB","address":"ALEMBIC PHARMACEUTICALS LTD\\r\\nALEMBIC ROAD","city":"VADODARA","supplier":"ALEMBIC PHARMACEUTICALS LIMITED","supplierCountry":"INDIA","foreign_port":"SEOUL - INCHEON INT\\'","customer":"BORYUNG PHARMACEUTICAL CO., LTD","customerCountry":"KOREA, REPUBLIC OF","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"12496","totalValueFC":"12366.1","currency":"USD","unitRateINR":900336.95999999996,"date":"19-Feb-2021","totalValueINR":"900336.96","totalValueInUsd":"12366.1","indian_port":"AHMEDABAD AIR","hs_no":"29331990","bill_no":"8775800","productDescription":"API","marketType":"REGULATED MARKET","country":"KOREA,REPUBLIC OF","selfForZScoreResived":"Pharma Grade","supplierPort":"AHMEDABAD AIR","supplierAddress":"ALEMBIC PHARMACEUTICALS LTD\\r\\nALEMBIC ROAD, VADODARA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"OLAPARIB","year":"2021","qtr":"Q2","strtotime":1621881000,"product":"OLAPARIB AS PER INVOICE","address":"ALEMBIC PHARMACEUTICALS LTD\\r\\nALEMBIC ROAD","city":"VADODARA","supplier":"ALEMBIC PHARMACEUTICALS LIMITED","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"TO THE ORDER OF?","customerCountry":"TURKEY","quantity":"0.25","actualQuantity":"0.25","unit":"KGS","unitRateFc":"14639.6","totalValueFC":"3600","currency":"USD","unitRateINR":1054784.8799999999,"date":"25-May-2021","totalValueINR":"263696.22","totalValueInUsd":"3600","indian_port":"AHMEDABAD AIR","hs_no":"29331990","bill_no":"1978993","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"AHMEDABAD AIR","supplierAddress":"ALEMBIC PHARMACEUTICALS LTD\\r\\nALEMBIC ROAD, VADODARA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q3","strtotime":1626978600,"product":"OLAPARIB","address":"ALEMBIC PHARMACEUTICALS LTD\\r\\nALEMBIC ROAD","city":"VADODARA","supplier":"ALEMBIC PHARMACEUTICALS LIMITED","supplierCountry":"INDIA","foreign_port":"YINCHUAN","customer":"OF","customerCountry":"KOREA, REPUBLIC OF","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"12781.1","totalValueFC":"12356.3","currency":"USD","unitRateINR":920878.55000000005,"date":"23-Jul-2021","totalValueINR":"920878.55","totalValueInUsd":"12356.3","indian_port":"AHMEDABAD AIR","hs_no":"29331999","bill_no":"3327588","productDescription":"API","marketType":"REGULATED MARKET","country":"KOREA,REPUBLIC OF","selfForZScoreResived":"Pharma Grade","supplierPort":"AHMEDABAD AIR","supplierAddress":"ALEMBIC PHARMACEUTICALS LTD\\r\\nALEMBIC ROAD, VADODARA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q3","strtotime":1627842600,"product":"OLAPARIB ( TAX INVOICE NO:1905215148 DT 29.07.2021","address":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR","city":"HYDERABAD, A.P.","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"DHAKA","customer":"RENATA LIMITED","customerCountry":"BANGLADESH","quantity":"1.50","actualQuantity":"1.5","unit":"KGS","unitRateFc":"12245.9","totalValueFC":"17844.5","currency":"USD","unitRateINR":882318.5,"date":"02-Aug-2021","totalValueINR":"1323477.75","totalValueInUsd":"17844.5","indian_port":"HYDERABAD AIR","hs_no":"29337990","bill_no":"3554386","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"BANGLADESH","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR, HYDERABAD, A.P.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q3","strtotime":1632940200,"product":"OLAPARIB","address":"ALEMBIC PHARMACEUTICALS LTD\\r\\nALEMBIC ROAD","city":"VADODARA","supplier":"ALEMBIC PHARMACEUTICALS LIMITED","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"TO THE ORDER OF","customerCountry":"ARGENTINA","quantity":"1.50","actualQuantity":"1.5","unit":"KGS","unitRateFc":"29000","totalValueFC":"40241.2","currency":"USD","unitRateINR":1973333.3333333333,"date":"30-Sep-2021","totalValueINR":"2960000","totalValueInUsd":"40241.2","indian_port":"AHMEDABAD AIR","hs_no":"29331999","bill_no":"4989883","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"AHMEDABAD AIR","supplierAddress":"ALEMBIC PHARMACEUTICALS LTD\\r\\nALEMBIC ROAD, VADODARA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q4","strtotime":1634063400,"product":"OLAPARIB IH","address":"HETERO HOUSE,H.NO.8-3-166\/7\/1ERRAGADDA","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"TUTEUR S.A.C.I.FI.A","customerCountry":"ARGENTINA","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"17000","totalValueFC":"16125.6","currency":"USD","unitRateINR":1208000,"date":"13-Oct-2021","totalValueINR":"1208000","totalValueInUsd":"16125.6","indian_port":"HYDERABAD AIR","hs_no":"29335990","bill_no":"5292495","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"HETERO HOUSE,H.NO.8-3-166\/7\/1ERRAGADDA, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1650393000,"product":"OLAPARIB (TAX INVOICE NO:1905225009 DATE","address":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD","city":"HYDERABAD","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"SEOUL","customer":"MASUNG & CO. ","customerCountry":"KOREA, REPUBLIC OF","quantity":"0.15","actualQuantity":"0.15","unit":"KGS","unitRateFc":"50000","totalValueFC":"7342.7","currency":"USD","unitRateINR":3693333.3333333335,"date":"20-Apr-2022","totalValueINR":"554000","totalValueInUsd":"7342.7","indian_port":"HYDERABAD AIR","hs_no":"29337990","bill_no":"9831216","productDescription":"API","marketType":"REGULATED MARKET","country":"KOREA,REPUBLIC OF","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1653589800,"product":"OLAPARIB","address":"ALEMBIC ROAD VADODARA Contact No: 919727727339","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LIMITED","supplierCountry":"INDIA","foreign_port":"AMMAN","customer":"TO THE ORDER OF","customerCountry":"JORDAN","quantity":"2.50","actualQuantity":"2.5","unit":"KGS","unitRateFc":"9000","totalValueFC":"22177.4","currency":"USD","unitRateINR":685600,"date":"27-May-2022","totalValueINR":"1714000","totalValueInUsd":"22177.4","indian_port":"AHMEDABAD AIR","hs_no":"29331999","bill_no":"1704900","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"JORDAN","selfForZScoreResived":"Pharma Grade","supplierPort":"AHMEDABAD AIR","supplierAddress":"ALEMBIC ROAD VADODARA Contact No: 919727727339, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1662575400,"product":"OLAPARIB API- BATCH NO. ON0030621 AS PER","address":"ZYDUS CORPORATE PARK, SCHEME NO 63, KHORAJ (GANDHINAGAR), NR. VAISHNODE","city":"AHMEDABAD","supplier":"ZYDUS LIFESCIENCES LIMITED","supplierCountry":"INDIA","foreign_port":"LOS ANGELES","customer":"BIODURO","customerCountry":"UNITED STATES","quantity":"2.50","actualQuantity":"2.5","unit":"KGS","unitRateFc":"7815.2","totalValueFC":"18667.1","currency":"USD","unitRateINR":598400,"date":"08-Sep-2022","totalValueINR":"1496000","totalValueInUsd":"18667.1","indian_port":"AHMEDABAD AIR","hs_no":"29337990","bill_no":"4040233","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"AHMEDABAD AIR","supplierAddress":"ZYDUS CORPORATE PARK, SCHEME NO 63, KHORAJ (GANDHINAGAR), NR. VAISHNODE, AHMEDABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1662575400,"product":"OLAPARIB API- BATCH NO.ON0040721 AS PER","address":"ZYDUS CORPORATE PARK, SCHEME NO 63, KHORAJ (GANDHINAGAR), NR. VAISHNODE","city":"AHMEDABAD","supplier":"ZYDUS LIFESCIENCES LIMITED","supplierCountry":"INDIA","foreign_port":"LOS ANGELES","customer":"BIODURO","customerCountry":"UNITED STATES","quantity":"2.50","actualQuantity":"2.5","unit":"KGS","unitRateFc":"7815.2","totalValueFC":"18667.1","currency":"USD","unitRateINR":598400,"date":"08-Sep-2022","totalValueINR":"1496000","totalValueInUsd":"18667.1","indian_port":"AHMEDABAD AIR","hs_no":"29337990","bill_no":"4040233","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"AHMEDABAD AIR","supplierAddress":"ZYDUS CORPORATE PARK, SCHEME NO 63, KHORAJ (GANDHINAGAR), NR. VAISHNODE, AHMEDABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1662575400,"product":"OLAPARIB API- BATCH NO.ON0050721 AS PER","address":"ZYDUS CORPORATE PARK, SCHEME NO 63, KHORAJ (GANDHINAGAR), NR. VAISHNODE","city":"AHMEDABAD","supplier":"ZYDUS LIFESCIENCES LIMITED","supplierCountry":"INDIA","foreign_port":"LOS ANGELES","customer":"BIODURO","customerCountry":"UNITED STATES","quantity":"2.50","actualQuantity":"2.5","unit":"KGS","unitRateFc":"7815.2","totalValueFC":"18667.1","currency":"USD","unitRateINR":598400,"date":"08-Sep-2022","totalValueINR":"1496000","totalValueInUsd":"18667.1","indian_port":"AHMEDABAD AIR","hs_no":"29337990","bill_no":"4040233","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"AHMEDABAD AIR","supplierAddress":"ZYDUS CORPORATE PARK, SCHEME NO 63, KHORAJ (GANDHINAGAR), NR. VAISHNODE, AHMEDABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1663525800,"product":"OLAPARIB (FORM-H) ONB5 (ON)","address":"A-2,419, CELEBRATION CITY CENTER,, GALA GYM ROAD,SOUTH BOPAL,BOPAL","city":"AHMEDABAD,GUJARAT","supplier":"APRAMEYA PHARMACHEM PVT LTD","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"AL SAHRA TRADE PETRO DMCC","customerCountry":"UNITED ARAB EMIRATES","quantity":"2.55","actualQuantity":"2.55","unit":"KGS","unitRateFc":"14730.8","totalValueFC":"36485.7","currency":"EUR","unitRateINR":1146666.6666666667,"date":"19-Sep-2022","totalValueINR":"2924000","totalValueInUsd":"36485.7","indian_port":"BOMBAY AIR","hs_no":"29337990","bill_no":"4276820","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"A-2,419, CELEBRATION CITY CENTER,, GALA GYM ROAD,SOUTH BOPAL,BOPAL, AHMEDABAD,GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1664735400,"product":"OLAPARIB (FORM-H) ONB5 (ON)","address":"A-2,419, CELEBRATION CITY CENTER,, GALA GYM ROAD,SOUTH BOPAL,BOPAL","city":"AHMEDABAD,GUJARAT","supplier":"APRAMEYA PHARMACHEM PVT LTD","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"AL SAHRA TRADE PETRO DMCC","customerCountry":"UNITED ARAB EMIRATES","quantity":"2.55","actualQuantity":"2.55","unit":"KGS","unitRateFc":"14730.8","totalValueFC":"35535.4","currency":"EUR","unitRateINR":1146666.6666666667,"date":"03-Oct-2022","totalValueINR":"2924000","totalValueInUsd":"35535.4","indian_port":"BOMBAY AIR","hs_no":"29337990","bill_no":"4602292","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"A-2,419, CELEBRATION CITY CENTER,, GALA GYM ROAD,SOUTH BOPAL,BOPAL, AHMEDABAD,GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1665081000,"product":"OLAPARIB (FORM-H) ONB5 (ON)","address":"A-2,419, CELEBRATION CITY CENTER,, GALA GYM ROAD,SOUTH BOPAL,BOPAL","city":"AHMEDABAD,GUJARAT","supplier":"APRAMEYA PHARMACHEM PVT LTD","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"AL SAHRA TRADE PETRO DMCC","customerCountry":"UNITED ARAB EMIRATES","quantity":"2.55","actualQuantity":"2.55","unit":"KGS","unitRateFc":"14730.8","totalValueFC":"36264.6","currency":"EUR","unitRateINR":1170196.0784313725,"date":"07-Oct-2022","totalValueINR":"2984000","totalValueInUsd":"36264.6","indian_port":"BOMBAY AIR","hs_no":"29337990","bill_no":"4663485","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"A-2,419, CELEBRATION CITY CENTER,, GALA GYM ROAD,SOUTH BOPAL,BOPAL, AHMEDABAD,GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1669660200,"product":"OLAPARIB PREMIX IH","address":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"SHEREMETYEVO","customer":"TO THE ORDER OF","customerCountry":"RUSSIA","quantity":"12.00","actualQuantity":"12","unit":"KGS","unitRateFc":"2500","totalValueFC":"27385.5","currency":"USD","unitRateINR":186250,"date":"29-Nov-2022","totalValueINR":"2235000","totalValueInUsd":"27385.5","indian_port":"HYDERABAD AIR","hs_no":"29335990","bill_no":"5806511","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"RUSSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1670005800,"product":"OLAPARIB IH","address":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR CONTA","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"TO THE ORDER OF","customerCountry":"ARGENTINA","quantity":"16.00","actualQuantity":"16","unit":"KGS","unitRateFc":"13000","totalValueFC":"200628","currency":"USD","unitRateINR":1033312.5,"date":"03-Dec-2022","totalValueINR":"16533000","totalValueInUsd":"200628","indian_port":"HYDERABAD AIR","hs_no":"29335990","bill_no":"5906138","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR CONTA, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1670524200,"product":"OLAPARIB DCG 25% W\/W (OTHER) (LUT (ARN)","address":"407\/408 SHARDA CHAMBERS,NEW MARINE LINES","city":"MUMBAI,MAHARASHTRA","supplier":"BDR PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"SINGAPORE","customer":"ALCAPTLT","customerCountry":"SINGAPORE","quantity":"0.70","actualQuantity":"700","unit":"GMS","unitRateFc":"4.9","totalValueFC":"3385.7","currency":"EUR","unitRateINR":398.57142857142856,"date":"09-Dec-2022","totalValueINR":"279000","totalValueInUsd":"3385.7","indian_port":"BOMBAY AIR","hs_no":"29420090","bill_no":"6032492","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"SINGAPORE","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"407\/408 SHARDA CHAMBERS,NEW MARINE LINES, MUMBAI,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1689877800,"product":"OLAPARIB","address":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD","city":"HYDERABAD","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"SEOUL - INCHEON INT\\'","customer":"TO THE ORDER OF","customerCountry":"KOREA, REPUBLIC OF","quantity":"3.00","actualQuantity":"3","unit":"KGS","unitRateFc":"10000","totalValueFC":"29517.1","currency":"USD","unitRateINR":808666.67700000003,"date":"21-Jul-2023","totalValueINR":"2426000.031","totalValueInUsd":"29517.1","indian_port":"HYDERABAD AIR","hs_no":"29337990","bill_no":"0","productDescription":"API","marketType":"REGULATED MARKET","country":"KOREA,REPUBLIC OF","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1690137000,"product":"OLAPARIB IH","address":"H.NO. 8-2-337,BESIDE TV9 OFFICE","city":"HYDERABAD ANDHRA PRADESH","supplier":"DR. REDDY\\'S LABORATORIES","supplierCountry":"INDIA","foreign_port":"NAN-T OU","customer":"ACTAVIS INC","customerCountry":"TAIWAN","quantity":"2.00","actualQuantity":"2","unit":"KGS","unitRateFc":"9540.7","totalValueFC":"18851.7","currency":"USD","unitRateINR":774707.5,"date":"24-Jul-2023","totalValueINR":"1549415","totalValueInUsd":"18851.7","indian_port":"Reddy r-SEZ\/Srikakulam","hs_no":"29335990","bill_no":"4000441","productDescription":"API","marketType":"REGULATED MARKET","country":"TAIWAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Reddy r-SEZ\/Srikakulam","supplierAddress":"H.NO. 8-2-337,BESIDE TV9 OFFICE, HYDERABAD ANDHRA PRADESH","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1690482600,"product":"OLAPARIB API","address":"ZYDUS TOWER, SARKHEJ-GANDHINAGAR,H","city":"AHMEDABAD,GUJARAT","supplier":"ZYDUS LIFESCIENCES LIMITED","supplierCountry":"INDIA","foreign_port":"LOS ANGELES","customer":"BIODURO","customerCountry":"UNITED STATES","quantity":"6.00","actualQuantity":"6","unit":"KGS","unitRateFc":"6576.2","totalValueFC":"38982","currency":"USD","unitRateINR":533985,"date":"28-Jul-2023","totalValueINR":"3203910","totalValueInUsd":"38982","indian_port":"Ahmedabad-ZIPL-SEZ","hs_no":"29337990","bill_no":"4004547","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Ahmedabad-ZIPL-SEZ","supplierAddress":"ZYDUS TOWER, SARKHEJ-GANDHINAGAR,H, AHMEDABAD,GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1691519400,"product":"OLAPARIB BATCH NO;OLBB022001","address":"NA","city":"BANGALORE","supplier":"ACEBRIGHT INDIA PHARMA PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"TAIPEI","customer":"LOTUS PHARMACEUTICAL CO LIMITED","customerCountry":"TAIWAN","quantity":"1.50","actualQuantity":"1.5","unit":"KGS","unitRateFc":"6000","totalValueFC":"8541.9","currency":"USD","unitRateINR":471721.614,"date":"09-Aug-2023","totalValueINR":"707582.421","totalValueInUsd":"8541.9","indian_port":"BANGALORE AIR","hs_no":"29339990","bill_no":"0","productDescription":"API","marketType":"REGULATED MARKET","country":"TAIWAN","selfForZScoreResived":"Pharma Grade","supplierPort":"BANGALORE AIR","supplierAddress":"NA, BANGALORE","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1691951400,"product":"OLAPARIB IH","address":"H.NO. 8-2-337,BESIDE TV9 OFFICE","city":"HYDERABAD ANDHRA PRADESH","supplier":"DR. REDDY\\'S LABORATORIES","supplierCountry":"INDIA","foreign_port":"NAN-T OU","customer":"ACTAVIS INC","customerCountry":"TAIWAN","quantity":"5.00","actualQuantity":"5","unit":"KGS","unitRateFc":"8121.1","totalValueFC":"40146.5","currency":"USD","unitRateINR":665116.80000000005,"date":"14-Aug-2023","totalValueINR":"3325584","totalValueInUsd":"40146.5","indian_port":"Reddy r-SEZ\/Srikakulam","hs_no":"29335990","bill_no":"4000512","productDescription":"API","marketType":"REGULATED MARKET","country":"TAIWAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Reddy r-SEZ\/Srikakulam","supplierAddress":"H.NO. 8-2-337,BESIDE TV9 OFFICE, HYDERABAD ANDHRA PRADESH","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1692642600,"product":"OLAPARIB IH","address":"H.NO. 8-2-337, BESIDE TV9 OFFICE,,","city":"HYDERABAD,TELANGANA","supplier":"DR. REDDY\\'S LABORATORIES","supplierCountry":"INDIA","foreign_port":"MONTREAL","customer":"PHARMASCIENCE INC","customerCountry":"CANADA","quantity":"2.00","actualQuantity":"2","unit":"KGS","unitRateFc":"8428.9","totalValueFC":"16728.3","currency":"USD","unitRateINR":692855,"date":"22-Aug-2023","totalValueINR":"1385710","totalValueInUsd":"16728.3","indian_port":"Reddy r-SEZ\/Srikakulam","hs_no":"29335990","bill_no":"4000523","productDescription":"API","marketType":"REGULATED MARKET","country":"CANADA","selfForZScoreResived":"Pharma Grade","supplierPort":"Reddy r-SEZ\/Srikakulam","supplierAddress":"H.NO. 8-2-337, BESIDE TV9 OFFICE,,, HYDERABAD,TELANGANA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1697653800,"product":"ACTIVE PHARMACEUTICALS INGREDIENTS - (API) OLAPARIB","address":"ALEMBIC ROAD","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LIMITED","supplierCountry":"INDIA","foreign_port":"SEOUL - INCHEON INT\\'","customer":"TO THE ORDER OF","customerCountry":"KOREA, REPUBLIC OF","quantity":"7.20","actualQuantity":"7.2","unit":"KGS","unitRateFc":"9000","totalValueFC":"63859.7","currency":"USD","unitRateINR":738194.44444444438,"date":"19-Oct-2023","totalValueINR":"5315000","totalValueInUsd":"63859.7","indian_port":"Ahmedabad Air","hs_no":"29331999","bill_no":"4760317","productDescription":"API","marketType":"REGULATED MARKET","country":"KOREA,REPUBLIC OF","selfForZScoreResived":"Pharma Grade","supplierPort":"Ahmedabad Air","supplierAddress":"ALEMBIC ROAD, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1703010600,"product":"OLAPARIB IH","address":"H.NO. 8-2-337,BESIDE TV9 OFFICE","city":"HYDERABAD ANDHRA PRADESH","supplier":"DR. REDDY\\'S LABORATORIES","supplierCountry":"INDIA","foreign_port":"MOSCOW DOMODEDOVO","customer":"AMEDART LLC","customerCountry":"RUSSIA","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"4789.6","totalValueFC":"4749.8","currency":"USD","unitRateINR":395385,"date":"20-Dec-2023","totalValueINR":"395385","totalValueInUsd":"4749.8","indian_port":"Reddy r-SEZ\/Srikakulam","hs_no":"29335990","bill_no":"4000819","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"RUSSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Reddy r-SEZ\/Srikakulam","supplierAddress":"H.NO. 8-2-337,BESIDE TV9 OFFICE, HYDERABAD ANDHRA PRADESH","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1707762600,"product":"OLAPARIB IH","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"TUTEUR S.A.C.I.F.I.A","customerCountry":"ARGENTINA","quantity":"19.18","actualQuantity":"19.18","unit":"KGS","unitRateFc":"11000","totalValueFC":"207627.9","currency":"USD","unitRateINR":898210.16684045887,"date":"13-Feb-2024","totalValueINR":"17227671","totalValueInUsd":"207627.9","indian_port":"Hyderabad Air","hs_no":"29335990","bill_no":"7489171","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1711564200,"product":"OLAPARIB IH","address":"H.NO. 8-2-337,BESIDE TV9 OFFICE","city":"HYDERABAD ANDHRA PRADESH","supplier":"DR. REDDY\\'S LABORATORIES","supplierCountry":"INDIA","foreign_port":"NAN-T OU","customer":"ACTAVIS INC","customerCountry":"TAIWAN","quantity":"5.00","actualQuantity":"5","unit":"KGS","unitRateFc":"7986.7","totalValueFC":"39555.6","currency":"USD","unitRateINR":656906.80000000005,"date":"28-Mar-2024","totalValueINR":"3284534","totalValueInUsd":"39555.6","indian_port":"Reddy r-SEZ\/Srikakulam","hs_no":"29332990","bill_no":"4000236","productDescription":"API","marketType":"REGULATED MARKET","country":"TAIWAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Reddy r-SEZ\/Srikakulam","supplierAddress":"H.NO. 8-2-337,BESIDE TV9 OFFICE, HYDERABAD ANDHRA PRADESH","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1716575400,"product":"OLAPARIB IH (GST TAX INV.SI3624200796 DT: 30.04.2024)","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"TO THE ORDER OF","customerCountry":"UNITED ARAB EMIRATES","quantity":"0.50","actualQuantity":"0.5","unit":"KGS","unitRateFc":"10000","totalValueFC":"5359.7","currency":"EUR","unitRateINR":893500,"date":"25-May-2024","totalValueINR":"446750","totalValueInUsd":"5359.7","indian_port":"Bombay Air","hs_no":"29335990","bill_no":"1152722","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1719340200,"product":"OLAPARIB IH (GST TAX INV.SI3624200796 DT: 30.04.2024)","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"TO THE ORDER OF","customerCountry":"UNITED ARAB EMIRATES","quantity":"0.50","actualQuantity":"0.5","unit":"KGS","unitRateFc":"10000","totalValueFC":"5276.7","currency":"EUR","unitRateINR":881000,"date":"26-Jun-2024","totalValueINR":"440500","totalValueInUsd":"5276.7","indian_port":"Bombay Air","hs_no":"29335990","bill_no":"1947978","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1726770600,"product":"ACTIVE PHARMACEUTICALS INGREDIENTS ? (API) (PHARMACEUTICALS RAW MATERIAL FOR PHARMA INDUSTRIES) PRODUCT NAME ? OLAPARIB","address":"ALEMBIC ROAD","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LIMITED","supplierCountry":"INDIA","foreign_port":"LISBON","customer":"\\\"TO THE ORDER OF\\\"","customerCountry":"PORTUGAL","quantity":"5.50","actualQuantity":"5.5","unit":"KGS","unitRateFc":"8000","totalValueFC":"43268.4","currency":"USD","unitRateINR":659263.30545454554,"date":"20-Sep-2024","totalValueINR":"3625948.18","totalValueInUsd":"43268.4","indian_port":"Ahmedabad Air","hs_no":"29331999","bill_no":"4185472","productDescription":"API","marketType":"REGULATED MARKET","country":"PORTUGAL","selfForZScoreResived":"Pharma Grade","supplierPort":"Ahmedabad Air","supplierAddress":"ALEMBIC ROAD, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1728239400,"product":"OLAPARIB 1H","address":"HETERO HOUSE,H.NO.8-3-166\/7\/1ERRAGADDA","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES","customer":"TUTEUR S.A.C.I.F.I.A","customerCountry":"ARGENTINA","quantity":"30.00","actualQuantity":"30","unit":"KGS","unitRateFc":"9000","totalValueFC":"264323.4","currency":"USD","unitRateINR":740339.33333333337,"date":"07-Oct-2024","totalValueINR":"22210180","totalValueInUsd":"264323.4","indian_port":"Hyderabad Air","hs_no":"29335990","bill_no":"4642259","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO HOUSE,H.NO.8-3-166\/7\/1ERRAGADDA, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1731349800,"product":"ACTIVEPHARMACEUTICALSINGREDIENTS(API)EXPORT INVOICENUMBER:F32512200871DT.08.11.2024 OLAPARIB","address":"PLOT 170-172, CHANDRAMOULI,INDUSTR","city":"SOLAPUR,MAHARASHTRA","supplier":"GLENMARK PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"SHEREMETYEVO APT\/MOS","customer":"TO THE ORDER","customerCountry":"RUSSIA","quantity":"0.50","actualQuantity":"0.5","unit":"KGS","unitRateFc":"756641","totalValueFC":"4348.8","currency":"INR","unitRateINR":733981,"date":"12-Nov-2024","totalValueINR":"366990.5","totalValueInUsd":"4348.8","indian_port":"Dahez-SEZ","hs_no":"29334900","bill_no":"5538644","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"RUSSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Dahez-SEZ","supplierAddress":"PLOT 170-172, CHANDRAMOULI,INDUSTR, SOLAPUR,MAHARASHTRA","customerAddress":""},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1669055400,"product":"OLAPARIB HOT MELT EXTRUDES (TEST LIC.NO. TL\/AZ\/22\/002757) FOR R & D PURPOSE NOT FOR SALE (FOC)","address":"ZYDUS CORPORATE PARK, SCHEME NO 63, KHORAJ (GANDHINAGAR), NR. VAISHNODE","city":"AHMEDABAD","supplier":"BIO DURO -SUNDIA","supplierCountry":"UNITED STATES","foreign_port":"NA","customer":"ZYDUS LIFESCIENCES LIMITED","customerCountry":"INDIA","quantity":"15.64","actualQuantity":"15.64","unit":"KGS","unitRateFc":"2350.9","totalValueFC":"38489.4","currency":"USD","unitRateINR":"200845.3","date":"22-Nov-2022","totalValueINR":"3141220.12","totalValueInUsd":"38489.4","indian_port":"BOMBAY AIR","hs_no":"29337990","bill_no":"3422337","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"ZYDUS CORPORATE PARK, SCHEME NO 63, KHORAJ (GANDHINAGAR), NR. VAISHNODE"}]
    19-Feb-2021
    12-Nov-2024
    KGS
    overview
    Loading...

    Average Price (USD/KGS)

    Number of Transactions

    Total Quantity (KGS)

    Total Value (USD)

    Quantity (KGS) & Unit rate (USD/KGS) over time

    API Imports and Exports

    Importing Country Total Quantity
    (KGS)    		 Average Price
    (USD/KGS)    		 Number of Transactions

    Upgrade, download data, analyse, strategize, subscribe with us contact

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Repare Doses First Patient in Phase 1 RP-3467 Trial Targeting Polθ in Cancer

    Details:

    RP-3467 is a Polθ ATPase inhibitor, small molecule drug candidate, which is being evaluated in combination with olaparib for the treatment of advanced solid tumors.


    Lead Product(s): RP-3467,Olaparib

    Therapeutic Area: Oncology Brand Name: RP-3467

    Study Phase: Phase IProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable October 14, 2024

    blank

    01

    Repare Therapeutics

    Canada
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed

    Repare Therapeutics

    Canada
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : RP-3467,Olaparib

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Repare Doses First Patient in Phase 1 RP-3467 Trial Targeting Polθ in Cancer

    Details : RP-3467 is a Polθ ATPase inhibitor, small molecule drug candidate, which is being evaluated in combination with olaparib for the treatment of advanced solid tumors.

    Brand Name : RP-3467

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    October 14, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Eisbach Doses First Patient in Phase 1/2 Trial for EIS-12656 in Refractory Solid Tumors

    Details:

    EIS-12656 targets ALC1 through allosteric mechanisms, suppressing the cancer-relevant genome reorganization induced by DNA damage. This leads to ALC1 chromatin trapping and cancer cell killing.


    Lead Product(s): EIS-12656,Olaparib

    Therapeutic Area: Oncology Brand Name: EIS-12656

    Study Phase: Phase I/ Phase IIProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable September 16, 2024

    blank

    02

    Eisbach Bio

    Denmark
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed

    Eisbach Bio

    Denmark
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : EIS-12656,Olaparib

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Eisbach Doses First Patient in Phase 1/2 Trial for EIS-12656 in Refractory Solid Tumors

    Details : EIS-12656 targets ALC1 through allosteric mechanisms, suppressing the cancer-relevant genome reorganization induced by DNA damage. This leads to ALC1 chromatin trapping and cancer cell killing.

    Brand Name : EIS-12656

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    September 16, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    FDA Approves FoundationOne®CDx As Companion Diagnostic for Prostate Cancer

    Details:

    Lynparza (olaparib) in combination with abiraterone and prednisone or prednisolone indicated for the treatment of adult patients with BRCA-mutated metastatic castration-resistant prostate cancer.


    Lead Product(s): Olaparib,Abiraterone Acetate,Prednisone

    Therapeutic Area: Oncology Brand Name: Lynparza

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Foundation Medicine

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable September 03, 2024

    blank

    03

    AstraZeneca

    United Kingdom
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed

    AstraZeneca

    United Kingdom
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Olaparib,Abiraterone Acetate,Prednisone

    Therapeutic Area : Oncology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Foundation Medicine

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    FDA Approves FoundationOne®CDx As Companion Diagnostic for Prostate Cancer

    Details : Lynparza (olaparib) in combination with abiraterone and prednisone or prednisolone indicated for the treatment of adult patients with BRCA-mutated metastatic castration-resistant prostate cancer.

    Brand Name : Lynparza

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    September 03, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Imfinzi approved in the US for endometrial cancer

    Details:

    Imfinzi (durvalumab) a PD-L1 inhibitor which is approved in combination with Lynparza (olaparib) for the treatment of advanced or recurrent endometrial cancer.


    Lead Product(s): Durvalumab,Olaparib,Carboplatin

    Therapeutic Area: Oncology Brand Name: Imfinzi

    Study Phase: ApprovedProduct Type: Large molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable June 17, 2024

    blank

    04

    AstraZeneca

    United Kingdom
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed

    AstraZeneca

    United Kingdom
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Durvalumab,Olaparib,Carboplatin

    Therapeutic Area : Oncology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Imfinzi approved in the US for endometrial cancer

    Details : Imfinzi (durvalumab) a PD-L1 inhibitor which is approved in combination with Lynparza (olaparib) for the treatment of advanced or recurrent endometrial cancer.

    Brand Name : Imfinzi

    Molecule Type : Large molecule

    Upfront Cash : Not Applicable

    June 17, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Olaparib Tablets Obtains Drug Registration Approval

    Details:

    Olaparib Tablets (100mg/150mg) has obtained drug registration approval granted by the National Medical Products Administration of the People’s Republic of China.


    Lead Product(s): Olaparib

    Therapeutic Area: Oncology Brand Name: Olaparib-Generic

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable June 03, 2024

    blank

    05

    CSPC Pharmaceutical Group

    China
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed

    CSPC Pharmaceutical Group

    China
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Olaparib

    Therapeutic Area : Oncology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Olaparib Tablets Obtains Drug Registration Approval

    Details : Olaparib Tablets (100mg/150mg) has obtained drug registration approval granted by the National Medical Products Administration of the People’s Republic of China.

    Brand Name : Olaparib-Generic

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    June 03, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Medivir´s licensee, Tango Therapeutics, has Discontinued Development of its TNG348 Program

    Details:

    TNG348 is a novel selective inhibitor of USP1 which is in phase 1/2 clinical trials as a single agent and in combination with olaparib, a PARP inhibitor, in patients with BRCA1/2-mutant cancers.


    Lead Product(s): TNG348,Olaparib

    Therapeutic Area: Oncology Brand Name: TNG348

    Study Phase: Phase I/ Phase IIProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable May 23, 2024

    blank

    06

    Tango Therapeutics

    U.S.A
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed

    Tango Therapeutics

    U.S.A
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : TNG348,Olaparib

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Medivir´s licensee, Tango Therapeutics, has Discontinued Development of its TNG348 Program

    Details : TNG348 is a novel selective inhibitor of USP1 which is in phase 1/2 clinical trials as a single agent and in combination with olaparib, a PARP inhibitor, in patients with BRCA1/2-mutant cancers.

    Brand Name : TNG348

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    May 23, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Merck Updates On Phase 3 KEYLYNK-006 Trial with KEYTRUDA® Plus LYNPARZA®

    Details:

    Keytruda (pembrolizumab) is being evaluated with Lynparza (olaparib), a PARP inhibitor, for metastatic nonsquamous non-small cell lung cancer.


    Lead Product(s): Pembrolizumab,Olaparib,Pemetrexed

    Therapeutic Area: Oncology Brand Name: Keytruda

    Study Phase: Phase IIIProduct Type: Large molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 21, 2024

    blank

    07

    Merck & Co

    U.S.A
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed

    Merck & Co

    U.S.A
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Pembrolizumab,Olaparib,Pemetrexed

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Merck Updates On Phase 3 KEYLYNK-006 Trial with KEYTRUDA® Plus LYNPARZA®

    Details : Keytruda (pembrolizumab) is being evaluated with Lynparza (olaparib), a PARP inhibitor, for metastatic nonsquamous non-small cell lung cancer.

    Brand Name : Keytruda

    Molecule Type : Large molecule

    Upfront Cash : Not Applicable

    March 21, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lynparza and Imfinzi Demonstrated Strong Benefit Doubling Median Duration Of Response

    Details:

    Imfinzi (durvalumab) with platinum-based chemotherapy followed by Lynparza (olaparib), demonstrated improved outcomes in patients with mismatch repair proficient advanced endometrial cancer.


    Lead Product(s): Durvalumab,Olaparib

    Therapeutic Area: Oncology Brand Name: Imfinzi

    Study Phase: Phase IIIProduct Type: Large molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 18, 2024

    blank

    08

    AstraZeneca

    United Kingdom
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed

    AstraZeneca

    United Kingdom
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Durvalumab,Olaparib

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Lynparza and Imfinzi Demonstrated Strong Benefit Doubling Median Duration Of Response

    Details : Imfinzi (durvalumab) with platinum-based chemotherapy followed by Lynparza (olaparib), demonstrated improved outcomes in patients with mismatch repair proficient advanced endometrial cancer.

    Brand Name : Imfinzi

    Molecule Type : Large molecule

    Upfront Cash : Not Applicable

    March 18, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Zydus Launches Anti-Cancer Generic Drug Olaparib in India

    Details:

    Ibyra (olaparib) is a poly (ADP-ribose) polymerase (PARP) inhibitor, which is approved in India for the treatment of HRD-positive and BRACA-positive cancer patients.


    Lead Product(s): Olaparib

    Therapeutic Area: Oncology Brand Name: Ibyra

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 13, 2024

    blank

    09

    Zydus Lifesciences

    India
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed

    Zydus Lifesciences

    India
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Olaparib

    Therapeutic Area : Oncology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Zydus Launches Anti-Cancer Generic Drug Olaparib in India

    Details : Ibyra (olaparib) is a poly (ADP-ribose) polymerase (PARP) inhibitor, which is approved in India for the treatment of HRD-positive and BRACA-positive cancer patients.

    Brand Name : Ibyra

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    March 13, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Tango Doses First Patient in Phase 1/2 Trial Of TNG348 for Cancers

    Details:

    TNG348 is a selective USP1 inhibitor in phase 1/2 trials, tested as a single agent and with olaparib for treating BRCA1/2-mutant or other HRD+ cancers.


    Lead Product(s): TNG348,Olaparib

    Therapeutic Area: Oncology Brand Name: TNG348

    Study Phase: Phase I/ Phase IIProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable January 03, 2024

    blank

    10

    Tango Therapeutics

    U.S.A
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed

    Tango Therapeutics

    U.S.A
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : TNG348,Olaparib

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Tango Doses First Patient in Phase 1/2 Trial Of TNG348 for Cancers

    Details : TNG348 is a selective USP1 inhibitor in phase 1/2 trials, tested as a single agent and with olaparib for treating BRCA1/2-mutant or other HRD+ cancers.

    Brand Name : TNG348

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    January 03, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    FDF Dossiers

    read-more
    read-more

    01

    Dr. Reddy's Laboratories

    India
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Lead Market Dossiers- Under Development

    Registration Country : India

    Olaparib

    Brand Name :

    Dosage Form : Oral Solid Dosage Form

    Dosage Strength : 100MG

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info : Lead Market Dossiers- Under Development

    Registration Country : India

    Dr Reddy Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Dr. Reddy's Laboratories

    India
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Lead Market Dossiers- Under Development

    Registration Country : India

    Olaparib

    Brand Name :

    Dosage Form : Oral Solid Dosage Form

    Dosage Strength : 150MG

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info : Lead Market Dossiers- Under Development

    Registration Country : India

    Dr Reddy Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Olpha

    Latvia
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothOlpha, a JSC AB City subsidiary, is a leading Baltic firm with 50 years of experience in medicines & chemical pharmaceuticals.

    Contact Supplier Contact Supplier
    Flag Latvia
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Dossier Readiness:Q3 2026

    Registration Country : Latvia

    Olaparib

    Brand Name :

    Dosage Form : Tablet

    Dosage Strength :

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info : Dossier Readiness:Q3 2026

    Registration Country : Latvia

    Olpha

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    AstraZeneca

    United Kingdom
    Pharma, Lab & Chemical Expo
    Not Confirmed
    arrow

    AstraZeneca

    United Kingdom
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : RX

    Registration Country : USA

    OLAPARIB

    Brand Name : LYNPARZA

    Dosage Form : TABLET;ORAL

    Dosage Strength : 150MG

    Packaging :

    Approval Date : 2017-08-17

    Application Number : 208558

    Regulatory Info : RX

    Registration Country : USA

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    AstraZeneca

    United Kingdom
    Pharma, Lab & Chemical Expo
    Not Confirmed
    arrow

    AstraZeneca

    United Kingdom
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Norway

    Olaparib

    Brand Name : Lynparza

    Dosage Form : Capsule, hard

    Dosage Strength : 50 mg

    Packaging : Bottle

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Norway

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    AstraZeneca

    United Kingdom
    Pharma, Lab & Chemical Expo
    Not Confirmed
    arrow

    AstraZeneca

    United Kingdom
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Originator

    Registration Country : South Africa

    Olaparib

    Brand Name : Lynparza 100

    Dosage Form : TAB

    Dosage Strength : 100mg

    Packaging : 56X1mg

    Approval Date :

    Application Number :

    Regulatory Info : Originator

    Registration Country : South Africa

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    AstraZeneca

    United Kingdom
    Pharma, Lab & Chemical Expo
    Not Confirmed
    arrow

    AstraZeneca

    United Kingdom
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Australia

    olaparib

    Brand Name : Lynparza

    Dosage Form :

    Dosage Strength :

    Packaging : 56

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Australia

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    AstraZeneca

    United Kingdom
    Pharma, Lab & Chemical Expo
    Not Confirmed
    arrow

    AstraZeneca

    United Kingdom
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Australia

    olaparib

    Brand Name : Lynparza

    Dosage Form :

    Dosage Strength :

    Packaging : 56

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Australia

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    AstraZeneca

    United Kingdom
    Pharma, Lab & Chemical Expo
    Not Confirmed
    arrow

    AstraZeneca

    United Kingdom
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Australia

    olaparib

    Brand Name : Lynparza

    Dosage Form :

    Dosage Strength :

    Packaging : 56

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Australia

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    AstraZeneca

    United Kingdom
    Pharma, Lab & Chemical Expo
    Not Confirmed
    arrow

    AstraZeneca

    United Kingdom
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Australia

    olaparib

    Brand Name : Lynparza

    Dosage Form :

    Dosage Strength :

    Packaging : 56

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Australia

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    FDA Orange Book

    read-more
    read-more

    01

    ASTRAZENECA

    United Kingdom
    Pharma, Lab & Chemical Expo
    Not Confirmed
    arrow

    ASTRAZENECA

    United Kingdom
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    RLD : Yes

    TE Code :

    OLAPARIB

    Brand Name : LYNPARZA

    Dosage Form : CAPSULE;ORAL

    Dosage Strength : 50MG

    Approval Date : 2014-12-19

    Application Number : 206162

    RX/OTC/DISCN : DISCN

    RLD : Yes

    TE Code :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    ASTRAZENECA

    United Kingdom
    Pharma, Lab & Chemical Expo
    Not Confirmed
    arrow

    ASTRAZENECA

    United Kingdom
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    RLD : Yes

    TE Code :

    OLAPARIB

    Brand Name : LYNPARZA

    Dosage Form : TABLET;ORAL

    Dosage Strength : 100MG

    Approval Date : 2017-08-17

    Application Number : 208558

    RX/OTC/DISCN : RX

    RLD : Yes

    TE Code :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    ASTRAZENECA

    United Kingdom
    Pharma, Lab & Chemical Expo
    Not Confirmed
    arrow

    ASTRAZENECA

    United Kingdom
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    RLD : Yes

    TE Code :

    OLAPARIB

    Brand Name : LYNPARZA

    Dosage Form : TABLET;ORAL

    Dosage Strength : 150MG

    Approval Date : 2017-08-17

    Application Number : 208558

    RX/OTC/DISCN : RX

    RLD : Yes

    TE Code :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Europe

    read-more
    read-more

    01

    AstraZeneca AB

    United Kingdom
    Pharma, Lab & Chemical Expo
    Not Confirmed
    arrow

    AstraZeneca AB

    United Kingdom
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Sweden

    olaparib

    Brand Name : Lynparza

    Dosage Form : HARD CAPSULES

    Dosage Strength : 50 MG

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Sweden

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    ASTRAZENECA AB

    United Kingdom
    Pharma, Lab & Chemical Expo
    Not Confirmed
    arrow

    ASTRAZENECA AB

    United Kingdom
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Italy

    Olaparib

    Brand Name : Lynparza

    Dosage Form : Olaparib 50Mg 448 Unita' Oral Use

    Dosage Strength : 448 cps 50 mg vial

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Italy

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    AstraZeneca AB (2)

    United Kingdom
    Pharma, Lab & Chemical Expo
    Not Confirmed
    arrow

    AstraZeneca AB (2)

    United Kingdom
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Norway

    Olaparib

    Brand Name : Lynparza

    Dosage Form : Capsule, hard

    Dosage Strength : 50 mg

    Packaging : Bottle

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Norway

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    AstraZeneca AG

    United Kingdom
    Pharma, Lab & Chemical Expo
    Not Confirmed
    arrow

    AstraZeneca AG

    United Kingdom
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Switzerland

    Olaparibum

    Brand Name : Lynparza

    Dosage Form : Filmtabl

    Dosage Strength : 100mg

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Switzerland

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    AstraZeneca AG

    United Kingdom
    Pharma, Lab & Chemical Expo
    Not Confirmed
    arrow

    AstraZeneca AG

    United Kingdom
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Switzerland

    Olaparibum

    Brand Name : Lynparza

    Dosage Form : Filmtabl

    Dosage Strength : 150mg

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Switzerland

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Olon Spa

    Italy
    Pharma, Lab & Chemical Expo
    Not Confirmed
    arrow

    Olon Spa

    Italy
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Italy
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Available Dossier- US-EU-RoW

    Registration Country : Italy

    Olaparib

    Brand Name :

    Dosage Form : Film Coated Tablet

    Dosage Strength : 100MG

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info : Available Dossier- US-EU-RoW

    Registration Country : Italy

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Olon Spa

    Italy
    Pharma, Lab & Chemical Expo
    Not Confirmed
    arrow

    Olon Spa

    Italy
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Italy
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Italy

    Olaparib

    Brand Name :

    Dosage Form : Film Coated Tablet

    Dosage Strength : 150MG

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Italy

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Listed Dossiers

    read-more
    read-more

    01

    Dr. Reddy's Laboratories

    India
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Lead Market Dossiers- Under De...

    Registration Country : India

    Olaparib

    Brand Name :

    Dosage Form : Oral Solid Dosage Form

    Dosage Strength : 100MG

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info : Lead Market Dossiers- Under De...

    Registration Country : India

    Dr Reddy Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    01

    Dr. Reddy's Laboratories

    India
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Packaging :

    Regulatory Info : Lead Market Dossiers- Under De...

    Olaparib

    Dosage : Oral Solid Dosage Form

    Dosage Strength : 100MG

    Brand Name :

    Approval Date :

    Application Number :

    Registration Country : India

    Dr Reddy Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Dr. Reddy's Laboratories

    India
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Lead Market Dossiers- Under De...

    Registration Country : India

    Olaparib

    Brand Name :

    Dosage Form : Oral Solid Dosage Form

    Dosage Strength : 150MG

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info : Lead Market Dossiers- Under De...

    Registration Country : India

    Dr Reddy Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Dr. Reddy's Laboratories

    India
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Packaging :

    Regulatory Info : Lead Market Dossiers- Under De...

    Olaparib

    Dosage : Oral Solid Dosage Form

    Dosage Strength : 150MG

    Brand Name :

    Approval Date :

    Application Number :

    Registration Country : India

    Dr Reddy Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Olpha

    Latvia
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothOlpha, a JSC AB City subsidiary, is a leading Baltic firm with 50 years of experience in medicines & chemical pharmaceuticals.

    Contact Supplier Contact Supplier
    Flag Latvia
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Dossier Readiness:Q3 2026

    Registration Country : Latvia

    Olaparib

    Brand Name :

    Dosage Form : Tablet

    Dosage Strength :

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info : Dossier Readiness:Q3 2026

    Registration Country : Latvia

    Olpha

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Olpha

    Latvia
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothOlpha, a JSC AB City subsidiary, is a leading Baltic firm with 50 years of experience in medicines & chemical pharmaceuticals.

    Contact Supplier Contact Supplier
    Flag Latvia
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Packaging :

    Regulatory Info : Dossier Readiness:Q3 2026

    Olaparib

    Dosage : Tablet

    Dosage Strength :

    Brand Name :

    Approval Date :

    Application Number :

    Registration Country : Latvia

    Olpha

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    TherDose Pharma

    India
    Pharma, Lab & Chemical Expo
    Not Confirmed
    arrow

    TherDose Pharma

    India
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : India

    Olaparib

    Brand Name :

    Dosage Form : Tablets

    Dosage Strength : 100mg

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : India

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    TherDose Pharma

    India
    Pharma, Lab & Chemical Expo
    Not Confirmed
    arrow

    TherDose Pharma

    India
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Packaging :

    Regulatory Info :

    Olaparib

    Dosage : Tablets

    Dosage Strength : 100mg

    Brand Name :

    Approval Date :

    Application Number :

    Registration Country : India

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    TherDose Pharma

    India
    Pharma, Lab & Chemical Expo
    Not Confirmed
    arrow

    TherDose Pharma

    India
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : India

    Olaparib

    Brand Name :

    Dosage Form : Tablets

    Dosage Strength : 150mg

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : India

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    TherDose Pharma

    India
    Pharma, Lab & Chemical Expo
    Not Confirmed
    arrow

    TherDose Pharma

    India
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Packaging :

    Regulatory Info :

    Olaparib

    Dosage : Tablets

    Dosage Strength : 150mg

    Brand Name :

    Approval Date :

    Application Number :

    Registration Country : India

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    XYZ Pharma

    Gabon
    Pharma, Lab & Chemical Expo
    Not Confirmed
    arrow

    XYZ Pharma

    Gabon
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Gabon
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Argentina

    Olaparib

    Brand Name :

    Dosage Form : Liquid-filled capsules

    Dosage Strength : 150MG

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Argentina

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    XYZ Pharma

    Gabon
    Pharma, Lab & Chemical Expo
    Not Confirmed
    arrow

    XYZ Pharma

    Gabon
    arrow
    Pharma, Lab & Chemical Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Gabon
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Packaging :

    Regulatory Info :

    Olaparib

    Dosage : Liquid-filled capsules

    Dosage Strength : 150MG

    Brand Name :

    Approval Date :

    Application Number :

    Registration Country : Argentina

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Excipients by Applications

    Click here to find the perfect excipient manufacturers by their capabilities

    Coating Systems & Additives

    read-more
    read-more

    Fillers, Diluents & Binders

    read-more
    read-more

    Controlled & Modified Release

    read-more
    read-more

    Direct Compression

    read-more
    read-more

    Film Formers & Plasticizers

    read-more
    read-more

    Chewable & Orodispersible Aids

    read-more
    read-more

    Taste Masking

    read-more
    read-more

    Lubricants & Glidants

    read-more
    read-more

    Disintegrants & Superdisintegrants

    read-more
    read-more

    Granulation

    read-more
    read-more

    Thickeners and Stabilizers

    read-more
    read-more

    Parenteral

    read-more
    read-more

    Co-Processed Excipients

    read-more
    read-more

    Empty Capsules

    read-more
    read-more

    API Stability Enhancers

    read-more
    read-more

    Coloring Agents

    read-more
    read-more

    Solubilizers

    read-more
    read-more

    Topical

    read-more
    read-more

    Vegetarian Capsules

    read-more
    read-more

    Emulsifying Agents

    read-more
    read-more

    Rheology Modifiers

    read-more
    read-more

    Surfactant & Foaming Agents

    read-more
    read-more

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    DATA COMPILATION #PharmaFlow

    read-more
    read-more

    STOCK RECAP #PipelineProspector

    read-more
    read-more

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    Market Place

    Do you need sourcing support? Ask us

    Patents & EXCLUSIVITIES

    Check the patents & exclusivity for this product

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search